论文部分内容阅读
对多耐药 (MDR)肺结核产生机理及应用二线结核药治疗方案进行探讨 ,并阐明安美汀作用机制。方法 采用中国防痨协会制定的结核分枝杆菌多耐药标准及疗效判定 ,对我院 10年来72例多耐药肺结核 ,应用抗结核二线药 (对照组 )与含安美汀抗结核二线药方案 (治疗组 )进行比较。结果 对 72例多耐药肺结核病例进行分析 ,治疗组与对照组 6个月胸片好转率及痰菌阴转率相比有显著差异 (P <0 .0 5)。结论 安美汀是一种新的、有效的、安全的抗结核药物
To investigate the mechanism of multi-drug resistant (MDR) pulmonary tuberculosis and the application of second-line drug regimens, and elucidate the mechanism of action. Methods The multi-resistant standard of Mycobacterium tuberculosis and curative effect determined by Chinese Antituberculosis Association were used to evaluate the efficacy of Mycobacterium tuberculosis in 72 cases of multi-resistant pulmonary tuberculosis in our hospital over the past 10 years. The anti-tuberculosis second-line drugs (control group) (Treatment group) for comparison. Results 72 cases of multi-resistant pulmonary tuberculosis cases were analyzed, the treatment group and control group 6 months rate of improvement of chest and sputum negative conversion rate was significantly different (P <0.05). Conclusion Avastin is a new, effective and safe anti-TB drug